Life Healthcare Group Limited (HK:0928)
:0928
Want to see HK:0928 full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/ADate:―
No summary available
Positive Factors
Financial Stability
A strong equity ratio and low debt-to-equity ratio suggest that the company is financially stable, providing a solid foundation for future growth and resilience against economic fluctuations.
Negative Factors
Compliance Challenges
Non-compliance with listing rules due to board changes may affect investor confidence and require swift action to restore compliance, impacting the company's governance reputation.
Read all positive and negative factors
Positive Factors
Negative Factors
Financial Stability
A strong equity ratio and low debt-to-equity ratio suggest that the company is financially stable, providing a solid foundation for future growth and resilience against economic fluctuations.
Read all positive factors
Life Healthcare Group (0928) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$146.18M
Dividend YieldN/A
Average Volume (3M)760.77K
Price to Earnings (P/E)7.2
Beta (1Y)0.67
Revenue Growth-58.65%
EPS Growth-370.13%
CountryHK
Employees13
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,850,425,000
10 Day Avg. Volume724,000
30 Day Avg. Volume760,773
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)1.32
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Life Healthcare Group Business Overview & Revenue Model
Company Description
King International Investment Ltd. is a holding company, which engages in providing healthcare products and services business. It operates through the following segments: Healthcare Products and Services Business, Money Lending Business, and Sales...
How the Company Makes Money
Life Healthcare Group generates revenue primarily through its hospital operations, which include patient fees for medical treatments, surgeries, and other healthcare services provided at its facilities. Diagnostic services contribute significantly...
Life Healthcare Group Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 40.77M | 233.68M | 223.85M | 92.87M | 102.04M |
| Gross Profit | 12.73M | 37.79M | 12.05M | 13.75M | 26.23M |
| EBITDA | -10.01M | 27.69M | -26.72M | -29.18M | 9.68M |
| Net Income | -47.45M | 15.82M | -25.19M | -34.46M | -4.58M |
Balance Sheet | |||||
| Total Assets | 286.36M | 336.13M | 264.27M | 302.94M | 325.01M |
| Cash, Cash Equivalents and Short-Term Investments | 309.00K | 473.00K | 17.79M | 37.40M | 8.57M |
| Total Debt | 2.37M | 5.71M | 6.73M | 422.00K | 715.00K |
| Total Liabilities | 63.72M | 70.08M | 31.27M | 39.56M | 30.32M |
| Stockholders Equity | 222.64M | 269.85M | 237.50M | 262.28M | 290.58M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -32.32M | -134.69M | 96.85M | -181.34M |
| Operating Cash Flow | 0.00 | -32.32M | -134.48M | 96.86M | -181.34M |
| Investing Cash Flow | 0.00 | 1.00K | 94.86M | -67.83M | -34.46M |
| Financing Cash Flow | 0.00 | 17.39M | 27.40M | -830.00K | 28.29M |
Life Healthcare Group Technical Analysis
Neutral
0.11
Price Trends
0.10
Negative
0.09
Negative
0.09
Negative
Market Momentum
>-0.01
Negative
44.28
Neutral
61.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0928, the sentiment is Neutral. The current price of 0.11 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.10, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.28 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0928.
Life Healthcare Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$146.18M | 7.17 | -16.81% | ― | -58.65% | -370.13% | |
66 Neutral | HK$1.49B | 4.60 | 39.78% | 9.92% | -23.31% | -44.61% | |
56 Neutral | HK$478.15M | -10.63 | 27.04% | ― | 2.00% | ― | |
52 Neutral | HK$1.63B | 256.57 | 0.48% | 0.49% | -2.63% | ― | |
50 Neutral | HK$551.12M | -20.98 | -10.69% | 1.72% | -3.49% | -1567.01% | |
49 Neutral | HK$207.34M | -0.67 | -17.38% | ― | -38.20% | -108.24% |
* Healthcare Sector Average
HK:0928
Life Healthcare Group
0.08
0.05
154.84%
HK:1830
Perfect Medical Health Management Limited
1.19
-0.82
-40.80%
HK:2138
EC Healthcare
0.47
-0.20
-29.55%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.09
<0.01
11.25%
HK:3869
Hospital Corporation of China Ltd
3.46
-3.34
-49.12%
HK:3886
Town Health International Medical Group Ltd.
0.24
>-0.01
-0.82%
Life Healthcare Group Corporate Events
King International Investment Limited Announces Annual General Meeting and Key Resolutions
Dec 16, 2025
King International Investment Limited has announced its upcoming annual general meeting scheduled for January 9, 2026. The meeting will address several key resolutions, including the adoption of audited financial statements, re-election of executi...
Coastal Greenland Limited Announces Change in Share Registrar Office
Dec 16, 2025
Coastal Greenland Limited, a company incorporated in the Cayman Islands, has announced a change in its Hong Kong Branch Share Registrar and Transfer Office. Effective from December 16, 2025, the company will transition its services to Tricor Inves...
King International Appoints New Co-Chairman to Boost Healthcare Strategy
Dec 4, 2025
King International Investment Limited has announced the appointment of Mr. Wang Jun as an executive director and co-chairman of the board, effective December 4, 2025. Mr. Wang brings extensive experience in biotechnology, regenerative medicine, an...
King International Investment Limited Announces New Board Composition
Dec 4, 2025
King International Investment Limited, a company incorporated in the Cayman Islands, has announced the composition of its board of directors effective from December 4, 2025. The board includes both executive and independent non-executive directors...
King International Investment Limited Reports Strong Interim Results for 2025
Nov 28, 2025
King International Investment Limited, a company incorporated in the Cayman Islands, has announced its interim results for the six months ended 30 September 2025. The company reported a significant increase in revenue, reaching HK$73,919,000 compa...
King International Investment Limited Schedules Board Meeting for Interim Results
Nov 14, 2025
King International Investment Limited, incorporated in the Cayman Islands, has announced a board meeting scheduled for November 28, 2025. The meeting will focus on approving the company’s interim results for the six months ending September 3...
King International Partners with Rongyuhe Group for Strategic Growth
Nov 5, 2025
King International Investment Limited has announced a strategic cooperation agreement with Rongyuhe Group Hong Kong Limited. This partnership aims to explore opportunities in the health industry, shopping malls, and baijiu business sectors, levera...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―